Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A
19841.4k citationsRobert E. Handschumacher, Matthew W. Harding et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Robert E. Handschumacher
Since
Specialization
Citations
This map shows the geographic impact of Robert E. Handschumacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Handschumacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Handschumacher more than expected).
Fields of papers citing papers by Robert E. Handschumacher
This network shows the impact of papers produced by Robert E. Handschumacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Handschumacher. The network helps show where Robert E. Handschumacher may publish in the future.
Co-authorship network of co-authors of Robert E. Handschumacher
This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Handschumacher.
A scholar is included among the top collaborators of Robert E. Handschumacher based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Robert E. Handschumacher. Robert E. Handschumacher is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Handschumacher, Robert E., et al.. (1996). Alternative protein ligands of calcineurin b: Ca++dependent interaction with tubulin and heat shock protein 60. The FASEB Journal. 10(3).1 indexed citations
Pizzorno, G, et al.. (1992). Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.. PubMed. 52(7). 1660–5.23 indexed citations
8.
Xu, Qing, María C. Leiva, Steven Fischkoff, Robert E. Handschumacher, & C. Richard Lyttle. (1992). Leukocyte chemotactic activity of cyclophilin.. Journal of Biological Chemistry. 267(17). 11968–11971.167 indexed citations
9.
Darnowski, James W. & Robert E. Handschumacher. (1988). Benzylacyclouridine. Biochemical Pharmacology. 37(13). 2613–2618.17 indexed citations
10.
Hait, W N, Jürgen M. Stein, Alan J. Koletsky, et al.. (1987). Modulation of doxorubicin dox resistance by cyclosporin a csa and a non immunosuppressive homolog. 28. 298.5 indexed citations
Summers, Wilma P. & Robert E. Handschumacher. (1973). The rate of mutation of L5178Y asparagine-dependent mouse leukemia cells to asparagine independence and its biological consequences.. PubMed. 33(7). 1775–9.17 indexed citations
Creasey, William A., et al.. (1963). Clinical and pharmacological studies with 2',3',5'-triacetyl-6-azauridine.. PubMed. 23. 444–53.57 indexed citations
Jaffe, Julian J., Robert E. Handschumacher, & Arnold D. Welch. (1957). Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine), in comparison with that of 6-azauracil.. PubMed. 30(3). 168–75.53 indexed citations
20.
Handschumacher, Robert E. & Arnold D. Welch. (1956). Microbial studies of 6-azauracil, an antagonist of uracil.. PubMed. 16(10 Part 1). 965–9.45 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.